Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases

Introduction: Tumor-induced osteomalacia is an acquired rare disease manifested by hypophosphatemic osteomalacia due to excessive secretion of fibroblast growth factor 23 (FGF23). FGF 23 is a non-classical hormone secreted by bone tissue (osteocytes) and regulates phosphorus metabolism.

The aim of this work is to present clinical experience in the diagnosis, treatment and rehabilitation of patients with tumor-induced osteomalacia.

Materials and methods: 40 patients with clinically-confirmed tumor-induced osteomalacia were included in the study, 34 of whom had the tumor localized, 27 underwent surgical treatment and 21 achieved stable remission.

Results: The median age was 48 [41; 63] years, 43% were men, the time left from the the onset of the disease was 8 [4; 10] years. Biochemical findings were hypophosphatemia 0.47 [0.4; 0.53] mmol/l, a decrease in the tubular reabsorption phosphate 62 [52; 67]%, and an increase in alkaline phosphatase of 183 [112; 294] units/l. At the time of diagnosis, 100% had multiple pathological fractures, only 10% could move independently, and 77.5% classified the pain as unbearable (8–10 points according to the 10-point pain syndrome scale ). Among the methods used to detect tumors, the most sensitive were scintigraphy with tectrotide with SPECT/CT 71.4% (20/28) and MRI 90% (18/20). In 35% of cases, the tumor was localized in soft tissues and in 65% in bone tissue; The tumor was most often detected in the lower extremities, followed by the head in frequency of localization. 18 patients currently have no remission and they receive conservative treatment (phosphorus and alfacalcidol n=15 and burosumab n=3). In case of achieving remission (n=21), regression of clinical symptoms and restoration of bone and muscle mass was observed. Extensive excision of the tumor without prior biopsy resulted in the best percentage of remission — 87%.

Conclusion: Tumor-induced osteomalacia is characterized by severe damage to bone and muscle tissue with the development of multiple fractures, muscle weakness and severe pain syndrome. In laboratory diagnostics, attention should be paid to hypophosphatemia, a decrease in the tubular reabsorption phosphate index and increased alkaline phosphatase. The use of functional diagnostic methods with a labeled somatostatin analogue to the subtype 2 receptor and MRI with contrast enhancement are the most accurate methods of topical diagnostics. In case of localization of the tumor, a wide excision without a preliminary biopsy is recommended.

1. Folpe AL. Phosphaturic mesenchymal tumors: A review and update. Semin Diagn Pathol. 2019;36(4):260-268. doi: https://doi.org/10.1053/j.semdp.2019.07.002

2. Florenzano P, Hartley IR, Jimenez M, et al. Tumor-induced osteomalacia. Calcif Tissue Int. 2021;108(1):128-142. doi: https://doi.org/10.1007/s00223-020-00691-6

3. Feng J, Jiang Y, Wang O, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017;64(7):675-683. doi: https://doi.org/10.1507/endocrj.EJ16-0587

4. Kobayashi H, Ito N, Akiyama T, et al. Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia. Int Orthop. 2017;41(12):2597-2603. doi: https://doi.org/10.1007/s00264-017-3610-3

5. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi: https://doi.org/10.1093/ageing/afy169

6. Rodionova SS, Snetkov AI, Akinshina AD, et al. Hypophosphatemic osteomalacia induced by FGF23-secreting tumor of the left femur. Rheumatol Sci Pract. 2019;57(6):708-712. (In Russ.) doi: https://doi.org/10.14412/1995-4484-2019-708-712

7. Auethavekiat P, Roberts JR, Biega TJ, et al. Difficult Diagnostic Cases. J Clin Oncol. 2005;23(15):3626-3628. doi: https://doi.org/10.1200/JCO.2005.05.043

8. Kinoshita Y, Takashi Y, Ito N, et al. Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO). Bone Reports. 2019;10(15):100192. doi: https://doi.org/10.1016/j.bonr.2018.100192

9. Grebennikova TA, Umiarova DS, Slashchuk KY, et al. Tumor-induced osteomalacia: a clinical case report. Osteoporosis and Bone Diseases. 2018;21(4):24-28. (In Russ.). doi: https://doi.org/10.14341/osteo10264

10. Rodionova SS. Metabolicheskie osteopatii: sistemnyj osteoporoz i osteomaljacija u vzroslyh. Mnisterstvo zdravoohranenija RSFSR: Central’nyj ordena Trudovogo Krasnogo Znameni nauchno-issledovatel’skij institut travmatologii i ortopedii im. NN. Priorova; 1992. (In Russ.).

11. Weidner N, Cruz DS. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59(8):1442-1454. doi: https://doi.org/10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q

12. Mak MP, da Costa e Silva VT, Martin RM, et al. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer. 2012;20(9):2195-2197. doi: https://doi.org/10.1007/s00520-012-1474-z

13. Layman AAK, Joshi S, Shah S. Metastatic prostate cancer presenting as tumour-induced osteomalacia. BMJ Case Rep. 2019;12(7):e229434. doi: https://doi.org/10.1136/bcr-2019-229434

14. Abramson M, Glezerman IG, Srinivasan M, et al. Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer. Clin Nephrol. 2021;95(2):104-111. doi: https://doi.org/10.5414/CN110242

15. Abate EG, Bernet V, Cortese C, Garner HW. Tumor induced osteomalacia secondary to anaplastic thyroid carcinoma: A case report and review of the literature. Bone Reports. 2016;5(2):81-85. doi: https://doi.org/10.1016/j.bonr.2015.11.004

16. Leaf DE, Pereira RC, Bazari H, Jüppner H. Oncogenic Osteomalacia due to FGF23-Expressing Colon Adenocarcinoma. J Clin Endocrinol Metab. 2013;98(3):887-891. doi: https://doi.org/10.1210/jc.2012-3473

17. Sauder A, Wiernek S, Dai X, et al. FGF23-Associated Tumor-Induced Osteomalacia in a Patient With Small Cell Carcinoma. Int J Surg Pathol. 2016;24(2):116-120. doi: https://doi.org/10.1177/1066896915617828

18. Gronskaya SA, Golounina OO, Buklemishev YV, et al. A clinical case of phosphopenic osteomalacia due to paraneoplastic secretion of metastatic prostate cancer. Osteoporosis and Bone Diseases. (In Russ.). doi: https://doi.org/10.14341/osteo12948

19. Rendina D, Abate V, Cacace G, D’Elia L, et al. Tumor-induced osteomalacia: A systematic review and individual patient’s data analysis. J Clin Endocrinol Metab. 2022;107(8):e3428-e3436. doi: https://doi.org/10.1210/clinem/dgac253

20. Endo I, Fukumoto S, Ozono K, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015;62(9):811-816. doi: https://doi.org/10.1507/endocrj.EJ15-0275

21. Carpenter TO. New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin North Am. 1997;44(2):443-466. doi: https://doi.org/10.1016/S0031-3955(05)70485-5

22. Kobayashi H, Ito N, Akiyama T, et al. Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia. Int Orthop. 2017;41(12):2597-2603. doi: https://doi.org/10.1007/s00264-017-3610-3

23. Eremkina AK, Mirnaya SS, Gorbacheva AM, et al. The case of oncogenic hypophosphatemic osteomalacia. Obesity and metabolism. 2020;17(2):220-227. (In Russ.). doi: https://doi.org/10.14341/omet12472

24. Lesnyak O, Gladkova E, Aleksandrov N, et al. Treatment of high fracture risk patients in routine clinical practice. Arch Osteoporos. 2020;15(1):184. doi: https://doi.org/10.1007/s11657-020-00851-z

25. Hidaka N, Koga M, Kimura S, et al. Clinical challenges in diagnosis, tumor localization and treatment of tumor‐induced osteomalacia: outcome of a retrospective surveillance. J Bone Miner Res. 2022;37(8):1479-1488. doi: https://doi.org/10.1002/jbmr.4620

26. Kawai S, Ariyasu H, Furukawa Y, et al. Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI. Endocrinol Diabetes Metab Case Reports. 2017;2017(8):1479-1488. doi: https://doi.org/10.1530/EDM-17-0005

27. El-Maouche D, Sadowski SM, Papadakis GZ, et al. 68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. J Clin Endocrinol Metab. 2016;101(10):3575-3581. doi: https://doi.org/10.1210/jc.2016-2052

28. Ito N, Shimizu Y, Suzuki H, et al. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med. 2010;268(4):390-394. doi: https://doi.org/10.1111/j.1365-2796.2010.02262.x

29. Andreopoulou P, Dumitrescu CE, Kelly MH, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res. 2011;26(6):1295-1302. doi: https://doi.org/10.1002/jbmr.316

30. Chong WH, Andreopoulou P, Chen CC, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res. 2013;28(6):1386-1398. doi: https://doi.org/10.1002/jbmr.1881

31. Wang H, Zhong D, Liu Y, et al. Surgical treatments of tumor-induced osteomalacia lesions in long bones: seventeen cases with more than one year of follow-up. J Bone Joint Surg Am. 2015;97(13):1084-1094. doi: https://doi.org/10.2106/JBJS.N.01299

32. Li X, Jiang Y, Huo L, et al. Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J Bone Miner Res. 2020;35(3):469-477. doi: https://doi.org/10.1002/jbmr.3903

33. Huang QL, Feig DS, Blackstein ME. Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest. 2000;23(4):263-267. doi: https://doi.org/10.1007/BF03343720

34. Gronskaia SA, Belaya ZE, Melnichenko GA. FGF23 tumor induced osteomalacia. Problems of Endocrinology. 2022;68(5):56-66. (In Russ.). doi: https://doi.org/10.14341/probl13130

35. Buchholz I, Janssen MF, Kohlmann T, Feng YS. A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics. 2018;36(6):645-661. doi: https://doi.org/10.1007/s40273-018-0642-5

36. Brooks R. EuroQol: the current state of play. Health Policy (New York). 1996;37(1):53-72. doi: https://doi.org/10.1016/0168-8510(96)00822-6

37. Savushkina NM, Amirdzhanova VN, Glukhova SI, et al. Validation of EQ-5D and HADS indices to evaluate quality of life in patients with panniculitis. Rheumatology Science and Practice. 2017;55(2):177-181 (In Russ.). doi: https://doi.org/10.14412/1995-4484-2017-177-181

38. Bollerslev J, Rejnmark L, Zahn A, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol. 2022;186(2):R33-R63. doi: https://doi.org/10.1530/EJE-21-1044

39. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity. Am J Surg Pathol. 2004;28(1):1-30. doi: https://doi.org/10.1097/00000478-200401000-00001

40. Hartley IR, Miller CB, Papadakis GZ, et al. Targeted FGFR blockade for the treatment of tumor-induced osteomalacia. N Engl J Med. 2020;383(14):1387-1389. doi: https://doi.org/10.1056/NEJMc2020399

41. Tella SH, Amalou H, Wood BJ, et al. Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia. J Bone Miner Res. 2017;32(11):2248-2256. doi: https://doi.org/10.1002/jbmr.3219

42. Kim M, Won CW. Prevalence of sarcopenia in community-dwelling older adults using the definition of the European Working Group on Sarcopenia in Older People 2: findings from the Korean Frailty and Aging Cohort Study. Age Ageing. 2019;48(6):910-916. doi: https://doi.org/10.1093/ageing/afz091

43. Ni X, Feng Y, Guan W, et al. Bone impairment in a large cohort of chinese patients with tumor-induced osteomalacia assessed by HR-pQCT and TBS. J Bone Miner Res. 2022;37(3):454-464. doi: https://doi.org/10.1002/jbmr.4476

44. Jan de Beur SM, Minisola S, Xia WB, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med. 2023;293(3):309-328. doi: https://doi.org/10.1111/joim.13593